SFI Awarded Prestigious ABC’s Tyler Award Given Global Research Effort

12 March 2015

Helsinn Group signs exclusive agreements with Mundipharma for distribution and licence of anamorelin in Brazil and across key markets in the Middle East and North Africa

11 February 2015

Helsinn Group signs exclusive agreement with Mundipharma for distribution and licensing of Netupitant/Palonosetron (nepa) in Brazil

10 February 2015

Helsinn and Zealand announce the advance of elsiglutide into Phase IIB development for the prevention of chemotherapyinduced diarrhea

6 February 2015

Helsinn Group grants stendhal international exclusive rights to the distribution and marketing of Netupitant-Palonosetron (nepa) in multiple countries of Latin America

3 February 2015

Helsinn awards scholarships for advanced synthesis

1 December 2014

Cerbios-Pharma SA and Lipidor AB strengthen partnership

18 August 2014

Helsinn Group and Gen Ilaç establish a collaboration for anamorelin in Turkey

12 July 2014

Helsinn to provide an independent educational grant support for a satellite symposium on Comprehensive Cancer Care

12 July 2014

Helsinn Therapeutics (U.S.), inc. Strengthens its board of directors

11 July 2014